Tamsulosin for benign prostatic hyperplasia
Authors:
- 7 September 2011
- journal article
- retraction
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2011 (9) , CD002081
Abstract
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate which can result in bothersome lower urinary tract symptoms. The treatment goal for men with BPH is to relieve these bothersome symptoms. This systematic review assessed the effects of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) compatible with BPH. Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers. Trials were eligible if they (1) randomized men with BPH to receive tamsulosin in comparison with placebo, other BPH medications or surgical interventions and (2) included clinical outcomes such as urologic symptom scales, symptoms, or urodynamic measurements, and (3) had a treatment duration of 30 days or longer. Eligibility was assessed by at least two independent observers. Information on patients, interventions, and outcomes were extracted by at least two independent reviewers using a standard form. The main outcome measure for comparing the effectiveness of tamsulosin with placebo, medical or surgical interventions was the change in urologic symptom scale scores. Secondary outcomes included changes in urinary flow measures (peak urine flow rate). The main outcome measure for adverse effects was the number of men reporting adverse effects. Fourteen studies involving 4122 subjects met inclusion criteria. Study duration ranged from 4 to 26 weeks, and no placebo-controlled study lasted longer than 13 weeks. The mean age of subjects was 64 years. Baseline symptom scores and urine flow rates demonstrated that men had moderate LUTS. Tamsulosin improved symptoms and peak urine flow relative to placebo. The weighted mean differences (WMD) for mean change from baseline for the Boyarsky symptom score for 0.4 mg and 0.8 mg doses of tamsulosin relative to placebo were -1.1 points (95% CI = -1.49 to -0.72; 12% improvement) and -1.6 points (95% CI = -2.3 to -1.0; 16% improvement), respectively. The WMD for mean change from baseline in peak urine flow were 1.1 mL/sec (95% CI = 0.59 to 1.51) and 1.1 mL/sec (95% CI= 0.65 to 1.48) for 0.4 mg and 0.8 mg, respectively. Tamsulosin (0.2 mg to 0.4 mg) was as effective as other alpha antagonists and the phytotherapeutic agent Permixon® in improving symptoms and flow rates though the doses of all alpha-antagonists studied may not have been optimal. Discontinuations from treatment for any reason and discontinuations "due to adverse events" were similar in the low dose tamsulosin (0.2 mg) and placebo groups but increased to 16% in trials utilizing a 0.8 mg dose of tamsulosin. Low dose tamsulosin was generally well tolerated although not all the trials reported specific adverse events. The most frequently reported adverse events that were significantly greater than placebo included dizziness, rhinitis and abnormal ejaculation. Adverse effects increased markedly as tamsulosin dosing increased, and were reported in 75% of men receiving the 0.8 mg dose. Men receiving a 0.2 mg dose tamsulosin were less likely to discontinue treatment compared to men receiving terazosin. Tamsulosin provided a small to moderate improvement in urinary symptoms and flow compared to men receiving placebo in men with BPH. Effectiveness was similar to other alpha antagonists and increased only slightly with higher doses. Long term effectiveness and ability to reduce complications due to BPH progression could not be determined. Adverse effects were generally mild but their frequency, including withdrawals, increased substantially with the higher doses that are generally available for treatment.Keywords
This publication has 31 references indexed in Scilit:
- A 6‐month large‐scale study into the safety of tamsulosinBritish Journal of Clinical Pharmacology, 2001
- The short-term effects of tamsulosin in Japanese men with benign prostatic hyperplasia.Nihon Ika Daigaku Zasshi, 1999
- A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 1998
- A dose‐ranging study of the efficacy and safety of tamsulosin, the first prostate‐selective &agr; 1A ‐adrenoceptor antagonist*, in patients with benign prostatic obstructionBritish Journal of Urology, 1997
- Clinical comparison of selective and non‐selective &agr; 1 A‐adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing dosesBritish Journal of Urology, 1997
- Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)British Journal of Urology, 1997
- Tamsulosin, a selective α 1c ‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophyEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986